World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial
New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
Researchers say a world-first cancer vaccine is delivering results even better than they had hoped for. The “transformational” breakthrough is detailed in a study that found a 42% reduction in the risk of melanoma recurrence.
